The antibiotic ciprofloxacin is used extensively to treat a wide range of infections caused by the opportunistic pathogen Pseudomonas aeruginosa. Due to its extensive use, the proportion of ciprofloxacin-resistant P. aeruginosa isolates is rapidly increasing. Ciprofloxacin resistance can arise through the acquisition of mutations in genes encoding the target proteins of ciprofloxacin and regulators of efflux pumps, which leads to overexpression of these pumps. However, understanding of the basis of ciprofloxacin resistance is not yet complete. Recent advances using high-throughput screens and experimental evolution combined with whole-genome sequencing and protein analysis are enhancing our understanding of the genetic and biochemical mechanisms involved in ciprofloxacin resistance. Better insights into the mechanisms of ciprofloxacin resistance may facilitate the development of new or improved therapeutic regimes effective against P. aeruginosa. In this review we discuss the current understanding of the mechanisms of ciprofloxacin resistance and summarize the genetic basis of ciprofloxacin resistance in P. aeruginosa, in the context of current and future use of this antibiotic.
INTRODUCTION
Pseudomonas aeruginosa is an opportunistic pathogen that causes a wide range of acute and chronic infections in patients who are immunocompromised or have other predisposing conditions [1] . It can infect almost all tissues [2] and is one of the most common causes of nosocomial infections [3, 4] . It chronically infects the lungs of patients with cystic fibrosis (CF) or with non-CF bronchiectasis, contributing to the decline in health of these patients [5, 6] . Chronic infections can last for years or even decades, during which time P. aeruginosa populations undergo thousands of generations of growth while facing challenges including antibiotic treatment, iron deprivation, immune system surveillance and interspecies competition [7] .
Ciprofloxacin is a member of the fluoroquinolone class of antibiotics that has been used successfully to treat a wide range of bacterial infections since 1987 and it is included in the World Health Organization's list of essential medicines. It remains one of the most important antibiotics in the treatment of P. aeruginosa infections. It is both the most effective fluoroquinolone against P. aeruginosa [8, 9] , and one of the most widely used antibiotics against this bacterium. It can be delivered orally or intravenously, and recently an inhalable ciprofloxacin formulation was developed for treating chronic P. aeruginosa infections in CF patients [10] . It has been used to treat a variety of P. aeruginosa infections including bacteraemia [11] , osteochondritis [12] , ear and eye infections [13] and malignant externa otitis [14] . It is commonly used for treatment of P. aeruginosa in children and adults with CF [15] . However, an increasing proportion of P. aeruginosa clinical isolates are resistant to ciprofloxacin. For example, in a study of CF patients in the United Kingdom, 30 % of P. aeruginosa isolates were ciprofloxacin resistant [16] . Similarly, over 40 % of isolates from Brooklyn, New York had at least partial ciprofloxacin resistance [17] .
Here we review the current understanding of the mechanism of action of ciprofloxacin and the biochemical and genetic changes underlying ciprofloxacin resistance in P. aeruginosa.
supercoiling process [21] . Similarly, topoisomerase IV is a tetramer of two ParC and two ParE subunits. These have similar functions to GyrA and GyrB; indeed, in P. aeruginosa GyrA and GyrB have 33 and 32 % amino acid sequence identity to ParC and ParE, respectively [22] . Topoisomerase IV is involved in resolving daughter chromosomes after DNA replication as well as relaxing supercoils in the DNA [19, 23] . Fluoroquinolones do not affect the strand breakage reactions catalysed by these enzymes but inhibit the religation step, resulting in cleaved DNA complexes that halt DNA replication. Thus, fluoroquinolones are generally bacteriostatic. However, high doses of fluoroquinolone can result in double-strand DNA breaks that are fatal to the affected cells [24, 25] .
The three-dimensional structures of DNA gyrase and topoisomerase IV from P. aeruginosa have not been determined but insights into their interactions with ciprofloxacin can be obtained from orthologous enzymes. In particular, the structure of the Mycobacterium tuberculosis DNA gyrase has recently been solved in complex with ciprofloxacin [26] , and topoisomerase IV from Acinetobacter baumannii has been solved in complex with the ciprofloxacin analogue moxifloxacin [27] . Ciprofloxacin is bound with high affinity through hydrogen bonding to amino acid side chains, with the interaction of enzyme and drug being bridged by magnesium (Mg 2+ ) ions and water molecules [27] .
The P. aeruginosa GyrA protein has 43 % sequence identity (60 % similarity) to GyrA from M. tuberculosis. We took advantage of this similarity to build a homology model of P. aeruginosa DNA gyraseA to shed light on its interactions with ciprofloxacin. In this model two key ciprofloxacin-binding residues are threonine 83 and aspartate 87 ( Fig. 1) . Identical or similar (serine and glutamate, respectively) residues are present at the corresponding positions in DNA gyrase and topoisomerase enzymes from other bacteria. These residues are at the DNA-binding site of DNA gyrase and topoisomerase and the presence of ciprofloxacin inhibits the resealing of DNA breaks, explaining why ciprofloxacin leads to DNA breakage in affected cells [18, 25, 28] .
Physiological responses to ciprofloxacin
Ciprofloxacin induces oxidative stress and the formation of hydroxyl radicals in P. aeruginosa through an unknown mechanism [29] . These may enhance the effectiveness of ciprofloxacin in killing P. aeruginosa; indeed, growth of the bacteria in the presence of hyperbaric oxygen increases their sensitivity to ciprofloxacin [30] .
Bacteria respond to DNA damage including single-and double-stranded breaks and replication blockage through the SOS response [31] . As might be expected, sub-inhibitory concentrations of fluoroquinolones, which results in the presence of double-stranded DNA breaks, induce the SOS response in a number of bacterial species including P. aeruginosa [32, 33] . This response involves increased expression of multiple genes encoding proteins associated with DNA repair, error-prone DNA polymerases and other related proteins [34] . Transcriptomic analysis of P. aeruginosa after exposure to sub-clinical levels of ciprofloxacin also showed induced expression of genes associated with DNA repair and recombination as well as genes encoding error-prone DNA polymerases [33, 35, 36] .
Enhanced production of error-prone DNA polymerases results in ciprofloxacin-induced increases in mutation frequencies in Escherichia coli [37, 38] and Streptococcus pneumoniae [39] . The same is likely to be the case in P. aeruginosa although so far as we are aware, the effect of ciprofloxacin on mutation rates has not been studied in P. aeruginosa.
Ciprofloxacin is thought to be more effective against actively growing cells. In P. aeruginosa, treatment with ciprofloxacin led to reduced expression of genes encoding proteins involved in cell division, motility, quorum sensing and cell permeability [33] . Downregulation of these genes may lead to reduction in cell growth rate, which might reduce the detrimental effects of ciprofloxacin. [25] . Subinhibitory concentration of ciprofloxacin also induced biofilm formation [40] . Growth in biofilms enhances the resistance of P. aeruginosa to antibiotics [41] including ciprofloxacin [42] [43] [44] .
Genetics and mechanisms of ciprofloxacin resistance There are two primary well-studied mechanisms of ciprofloxacin resistance in P. aeruginosa, target-site modification and upregulation of efflux pumps (Fig. 2) . Mutations in the ciprofloxacin target-encoding genes gyrAB and parCE reduce the affinity of DNA gyrase or topoisomerase for ciprofloxacin. Overexpression of efflux pumps increases the expulsion of ciprofloxacin from P. aeruginosa cells and occurs through mutations in regulatory genes of efflux pumps. It has become clear that a large number of other genes can also play a role in ciprofloxacin resistance and resistance is evolved by combination of alleles, highlighting the complexity and multifactorial nature of the ciprofloxacin-resistance development process [45, 46] .
Target-site modification
Mutations in genes encoding DNA gyrase and topoisomerase IV are major contributors to ciprofloxacin resistance in P. aeruginosa (Table 1) . Mutations associated with ciprofloxacin resistance in P. aeruginosa were first identified in gyrA [47] . Subsequent studies have shown that sequence variants in which the threonine at position 83 in GyrA is replaced by an isoleucine and the serine at position 87 in ParC is replaced by a leucine are the most frequently occurring alterations associated with ciprofloxacin resistance in P. aeruginosa from CF, non-CF and in vitro evolved isolates [48] [49] [50] [51] [52] . The second most frequent variant in GyrA is at position 87, with asparagine, tyrosine or glycine residues being present in place of aspartate. In our model of GyrA, Thr83 and Asp87 play key roles in the binding of ciprofloxacin by DNA gyrase through water-ion bridges (Fig. 1) . The presence of different amino acid residues at these sites reduces the affinity of gyrase for ciprofloxacin, providing a mechanistic explanation for the higher ciprofloxacin resistance conferred by the GyrA variants [53] [54] [55] . This resistance mechanism was supported when drug-binding assays showed reduced affinity of mutant E. coli GyrA for ciprofloxacin, compared to the wild-type gyrase enzyme [56] . GyrA and ParC variants occur more frequently than GyrB and ParE variants (Table 1) , perhaps because changes in the sequences of GyrB and ParE confer lower-level resistance to ciprofloxacin. Reduced binding of ciprofloxacin to DNA gyrase or topoisomerase will reduce the frequency of singleand double-strand DNA breaks (Fig. 2) .
The high prevalence of the isoleucine variant at position 83 in GyrA implies that other than greatly increasing resistance to ciprofloxacin this has little or no effect on the fitness of P. aeruginosa. This is consistent with studies in other species that showed that equivalent mutations reduced quinolone binding without affecting enzyme activity [54, 57] . Other factors such as secondary site mutations may also play a role in reducing disadvantageous effects of resistance alleles [58] .
Efflux overexpression
The second major mechanism of ciprofloxacin resistance is increased efflux from cells, to reduce the intracellular concentration (Fig. 2) . Efflux pumps secrete small molecules such as antibiotics, dyes, detergents, inhibitors, disinfectants, organic solvents and homoserine lactones [59] . Each efflux system is composed of a cytoplasmic membrane-spanning substrate-proton antiporter protein, an outer membrane channel-forming protein and a bridging periplasmic membrane fusion protein [60, 61] . Efflux is an energy-dependent process driven by an ATPase in the cytoplasmic membrane component. Efflux pumps commonly secrete multiple chemically related substrates. P. aeruginosa contains 12 efflux pumps [62] and four of these are known to efflux fluoroquinolones: MexCD-OprJ, MexEF-OprN, MexAB-OprM and MexXY-OprM [63] [64] [65] [66] . Expression of efflux pump genes is controlled by systemspecific regulatory proteins and efflux pump overexpression occurs through mutations in these regulators [65, 67, 68] .
Overexpression of two efflux pumps MexCD-OprJ and MexEF-oprN have been most commonly reported as contributing in ciprofloxacin resistance. Overexpression of MexCD-OprJ arises through mutations in the nfxB gene [58, 69] and occurs in P. aeruginosa isolates from CF and non-CF patients [52, 70, 71] . Mutations resulting in overexpression of MexCD-OprJ occur at a range of positions in nfxB in fluoroquinolone-resistant isolates of P. aeruginosa [71] [72] [73] . Wild-type NfxB binds to the promoter of the mexCD-oprJ operon as a dimer, repressing transcription. Mutations inhibit the dimerisation and DNA binding of NfxB, enhancing production of the MexCD-OprJ efflux pump, which leads to multidrug resistance [74, 75] . Overexpression of MexEF-OprN also occurs in isolates of P. aeruginosa from CF and non-CF patients due to mutations in the mexS gene, which result in overexpression of MexT. MexT is an activator involved in the upregulation of the MexEFoprN genes [65, 71] , although there are likely to be additional regulators that remain to be identified [76] . In addition, overexpression of mexXY-oprM has also been shown to confer ciprofloxacin resistance at lower levels in clinical isolates of P. aeruginosa [49, 77] . Overexpression of mexXY-oprM has mostly been attributed to mutations in regulator gene mexZ [78, 79] .
Resistance is enhanced by combinations of alleles Clinically resistant P. aeruginosa isolates often have mutations associated with ciprofloxacin resistance in multiple different genes. These are typically alleles associated with high-level expression of efflux pumps accompanied by resistance alleles of ciprofloxacin target-site proteins [48, 49, 72, [80] [81] [82] [83] [84] . Ciprofloxacin-resistant isolates frequently have target-site mutations in both DNA gyrase (gyrA and/or gyrB) and topoisomerase IV (parC and/or parE). A combination of gyrA and parC resistance alleles confers higher ciprofloxacin resistance than resistance alleles in only gyrA in clinical isolates of P. aeruginosa [85] [86] [87] [88] [89] [90] . Bacteria with target-site mutations as well as efflux overexpression had higher ciprofloxacin resistance than bacteria with only individual mutations [49, 91] . Overexpression of two efflux systems did not further enhance resistance.
The relative contributions of mutant gyrA and of other genes to resistance has been investigated by restoring gyrA to the wild-type sequence in ciprofloxacin-resistant isolates of P. aeruginosa [49] . Restoration of wild-type gyrA reduced the ciprofloxacin MIC in all cases, but by different amounts in different isolates. The different MICs of different isolates with restored wild-type gyrA indicate the presence of additional strain-variable resistance mechanisms.
Experimental evolution studies suggest that mutation to a gyrA resistance allele is essential for ciprofloxacin resistance, with other mutations further increasing resistance [92] . Bacteria with mutations in regulatory genes of efflux pumps but with a wild-type gyrA allele may remain ciprofloxacinsusceptible due to the high affinity of wild-type GyrA for ciprofloxacin [49, 89, 93] .
The presence of ciprofloxacin-resistant P. aeruginosa within patients may arise from infection by a ciprofloxacin-resistant strain, or alternatively through infection with a ciprofloxacin-sensitive strain that evolves during the course of infection to become resistant. Whole-genome sequencing of P. aeruginosa isolated at different times from the lungs of chronically infected CF patients provides an opportunity to identify mutations that occur during infection. In an analysis of 26 samples isolated over a 19-year period from patients in Denmark who had received ciprofloxacin treatment, positive selection had occurred for mutations in gyrA, gyrB, mexA, mexB, nfxB and mexZ [94] , all of which are associated with ciprofloxacin resistance.
Other ciprofloxacin resistance genes
The development of tools for high-throughput wholegenome analysis has provided additional approaches to identify genes and proteins that contribute to ciprofloxacin resistance. The availability of transposon mutant libraries, collections of mutants that between them have a transposon insertion in each mutable gene, has led to the identification of more than 100 genes in which mutations alter the resistance of P. aeruginosa to ciprofloxacin by two to fourfold, including unexpected genes such as mutS and mutL that encode mismatch repair proteins, bacteriophage genes, nuoD that encodes a component of NADH dehydrogenase and iron transport genes [45] . Overall, 35 of the mutants had lower resistance than wild-type, identifying genes that contribute to basal resistance and may represent novel targets for future drug interventions. The clinical relevance of these genes has not yet been studied.
A few studies have used an alternative approach of developing ciprofloxacin-resistant mutants from sensitive strains in laboratory culture and then using whole-genome sequencing to identify the mutations (Table 2) . These experimental evolution studies have advantages over investigating ciprofloxacin-resistant clinical isolates, which often have thousands of genetic differences masking those associated with ciprofloxacin resistance. A number of genes including gyrA, gyrB, nfxB and parC were commonly mutated in laboratory-evolved ciprofloxacin-resistant mutants, as might be expected. Notably, mutations gyrA T83I and parC S87L/N were frequently obtained, indicating that these mutations are strongly associated with ciprofloxacin resistance. In addition, some novel genes associated with ciprofloxacin resistance were identified (Table 2) . However, how these mutations contribute to resistance and their clinical relevance has not been studied yet. These studies show the potential of experimental evolution to reveal previously unidentified resistance mechanisms.
Laboratory-evolved mutants of P. aeruginosa with increased ciprofloxacin resistance have also been analysed using proteomics approaches [95, 96] . Increased phosphorylation of two proteins, succinate-semialdehyde dehydrogenase and methyl malonate-semialdehyde dehydrogenase, and increased expression of a protein of unknown function occurred during development of resistance [95] . The protein changes may contribute to resistance by affecting production of ATP that is required for activity of efflux pumps and other processes or may be involved in increased production of NADH to reduce oxidative stress [95] . A second study also found that reduced oxidative stress was associated with resistance to ciprofloxacin, through adoption of anaerobic respiration and upregulation of catalase and peroxidase [96] . Other changes associated with resistance involved increased production of proteins involved in DNA *Amino acid changes associated with ciprofloxacin resistance. †The range of frequency of resistance alleles in different studies.
Rehman -10 repair and of proteins for import of iron and polyamine. Highly resistant mutants showed overexpression of MexCD-OprJ and reduced expression of quorum sensing proteins [96] .
In other Gram-negative bacteria, ciprofloxacin resistance can involve acquisition of resistance genes on mobile genetic elements such as plasmids [97] . This mechanism is rare in P. aeruginosa, although a few examples have been reported [98] [99] [100] . In the clearest case, a plasmid-borne gene encodes an enzyme that catalyses phosphorylation of ciprofloxacin, inactivating it [98] . In three other examples, genes associated with ciprofloxacin resistance in other species have been identified at a low frequency on mobile genetic elements in P. aeruginosa [99] [100] [101] , although their contributions to resistance in this species remain to be determined.
Collectively, the diverse approaches described above show that ciprofloxacin resistance can involve multiple proteins and can be a multifaceted process.
Future perspectives
Extensive use of ciprofloxacin has resulted in emergence of resistant bacteria that may render the drug ineffective [102] . The increasing frequency of ciprofloxacin-resistant P. aeruginosa highlights the need for identifying improved treatment regimens to prolong its effectiveness. A number of approaches are being investigated. For example, targeting ciprofloxacin more precisely to the site of infection, by using inhaled liposomal formulations for respiratory infections, can increase the effective dose and may reduce the development of ciprofloxacin resistance [103] . A possible complementary approach that is being explored is to use combination therapies, in which ciprofloxacin is co-administered with a second anti-Pseudomonas antibiotic.
Combination therapies provide a promising alternative to using antibiotics alone as they can reduce the rate of occurrence of resistant mutants [104] [105] [106] [107] [108] . Recognition that antibiotic resistance can confer fitness costs in the absence of antibiotics, with antibiotic-sensitive strains having a growth advantage, has also led to the concept of antibiotic treatment 'holidays' that may minimize the frequency of resistant strains [109] . There is some evidence that this approach can reduce and reverse fluoroquinolone resistance [110, 111] .
There is also increasing recognition of the occurrence of collateral sensitivity in which resistance to one antibiotic results in increased sensitivity to an unrelated antibiotic, in a range of microbial species [112, 113] . P. aeruginosa resistant to one drug and with collateral sensitivity to another have been reported in laboratory-evolved bacteria as well as in isolates from CF and non-CF patients [113] [114] [115] [116] . The mechanisms involved in collateral sensitivity in P. aeruginosa are not well understood. Possible mechanisms for collateral sensitivity of ciprofloxacin-resistant P. aeruginosa to other antibiotics could be altered proton motive force (PMF)-mediated efflux pump activity [114] , decreased induction of AmpC b-lactamase [115] , mutations in nfxB [80, [115] [116] [117] and genomic reprogramming resulting from alterations in DNA supercoiling [113] . Exploitation of collateral sensitivity in chemotherapeutic regimens for ciprofloxacin-resistant P. aeruginosa may provide a promising approach for clinical treatments, while also reducing the frequency of ciprofloxacin-resistant bacteria [112] . In contrast to collateral sensitivity, a number of studies have investigated the role of ciprofloxacin in cross resistance to other antibiotics [59, 80, [118] [119] [120] [121] [122] . Resistance can arise more readily because of the increased rate of mutation associated with ciprofloxacin treatment [122] . Furthermore, increased activity of efflux pumps that contributes to ciprofloxacin resistance can also increase resistance to other antibiotics [73] . Given the threat posed by multidrug-resistant strains of P. aeruginosa, further research is needed to clarify the role of ciprofloxacin in emergence of resistance and sensitivity to other antibiotics, and in particular the implications for clinical treatment.
The primary mechanisms that confer ciprofloxacin resistance in P. aeruginosa are relatively well understood. However, laboratory-based studies have identified mutations in a number of other genes that may also contribute to resistance. The importance of these mechanisms in the clinical setting remains to be determined but identification of other genes that contribute to resistance in clinical isolates of P. aeruginosa may lead to novel targets for anti-Pseudomonas drugs. There is increasing interest in the use of wholegenome analysis of infectious bacteria as a clinical tool to rapidly predict antibiotic resistance profiles and hence guide patient treatment [123] [124] [125] . Current understanding of the genetic basis of ciprofloxacin resistance in P. aeruginosa indicates that this approach is realistic in this case, but a complete knowledge of resistance-associated mutations will be required for robust predictions of ciprofloxacin resistance.
In conclusion, the use of ciprofloxacin as a key tool in the management of P. aeruginosa infections, in a wide range of clinical settings, means that there is a high degree of urgency and importance in maintaining its effectiveness as an antibiotic. Doing so will require better understanding of how resistance develops and incorporation of that understanding into clinical practice through approaches such as more directed treatment regimes, exploitation of collateral sensitivity, combination therapy or real-time genetic analysis of infecting bacteria. 
